Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | HPGD | P15428 | 7/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | KIT | P10721 | 2/20 | 0.67 |
| ▸ | FLT3 | P36888 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 15/20 | 0.64 |
| ▸ | GAA | P10253 | 7/20 | 0.64 |
| ▸ | GFER | P55789 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770393 | 0.85 | MAPT (0.66) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL769665 | 0.85 | RAB9A (0.71) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL769090 | 0.85 | KIT (0.77) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL13305000 | 0.81 | RAB9A (0.67) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL16656626 | 0.81 | RAB9A (0.66) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL13305089 | 0.80 | KDM4E (0.69) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL13329937 | 0.80 | RAB9A (0.64) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL769285 | 0.79 | MAPT (0.70) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL770130 | 0.79 | MAPT (0.70) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL769341 | 0.79 | MAPT (0.70) | RAB9AKDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629170-B2 | Anti-viral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-14 | — | — | US | claimed |
| EP-1988776-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC (US) | 2012-08-08 | — | — | EP | claimed |
| US-20110172281-A1 | Anti-Viral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2011-07-14 | — | — | US | claimed |
| US-7977365-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-07-12 | — | — | US | claimed |
| US-7872037-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | claimed |
| EP-1988776-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007103111-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8629170-B2 | Anti-viral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629170-B2 | Anti-viral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2007103111-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172281-A1 | Anti-Viral Drugs for Treatment of Arenavirus Infection | GK, GALK1, KLK7 | RAB9A 3813/4885KDM4E 1888/4885ALDH1A1 4463/4885 |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | GK, GALK1, GZMB | RAB9A 3895/4885KDM4E 1925/4885ALDH1A1 4481/4885 |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | GK, MAVS, ZC3HAV1 | RAB9A 3470/4885KDM4E 2293/4885ALDH1A1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.